Fibroblast glutamate transport in aging and in AD: correlations with disease severity

Altered glutamate transport and aberrant EAAT1 expression were shown in Alzheimer’s disease (AD) brains. It is presently unknown
whether these modifications are a consequence of neurodegeneration or play a pathogenetic role. However, recent findings of decreased
glutamate uptake, EAAT1 protein and mRNA in AD platelets suggest that glutamate transporter modifications may be systemic and might
explain the decreased glutamate uptake. We now used primary fibroblast cultures from 10 AD patients to further investigate the specific
involvement of glutamate transporters in this disorder and in normal aging. Decreased glutamate uptake (p < 0.001), EAAT1 expression
(p < 0.05) and mRNA (p < 0.01) were observed in aged people, compared to younger controls. In AD fibroblasts, compared to age-matched
controls, we observed further reductions of glutamate uptake (p < 0.0005) and EAAT1 expression (p < 0.005), while EAAT1 mRNA increase
(p < 0.001) was shown. EAAT1 parameters were mutually correlated (p < 0.01) and correlations were shown with dementia severity (p < 0.05
MMSE-expression, p < 0.005 MMSE-mRNA). We suggest fibroblast cultures as possible ex vivo peripheral model to study the glutamate
involvement and possible molecular and therapeutic targets in AD.